Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 6/20 | 0.65 |
| ▸ | PLK1 | P53350 | 1/20 | 0.65 |
| ▸ | THRA | P10827 | 7/20 | 0.62 |
| ▸ | THRB | P10828 | 7/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | RARA | P10276 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | MTOR | P42345 | 1/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.56 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.53 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12648633 | 0.92 | THRA (0.67) | RARBTHRATHRBALDH1A1MEN1 | |
| SCHEMBL15100965 | 0.87 | PLK1 (0.62) | RARBPLK1THRATHRBALDH1A1 | |
| SCHEMBL13950912 | 0.85 | RARB (0.67) | RARBPLK1THRATHRBALDH1A1 | |
| SCHEMBL1404028 | 0.85 | RARB (0.67) | RARBPLK1THRATHRBALDH1A1 | |
| SCHEMBL2564366 | 0.85 | RARB (0.67) | RARBPLK1THRATHRBALDH1A1 | |
| SCHEMBL181230 | 0.83 | RARB (0.89) | RARBPLK1THRATHRBALDH1A1 | |
| SCHEMBL967078 | 0.83 | HSD17B10 (0.67) | RARBPLK1THRATHRBALDH1A1 | |
| SCHEMBL9693784 | 0.83 | RARB (0.65) | RARBPLK1THRATHRBALDH1A1 | |
| SCHEMBL14679132 | 0.82 | THRA (0.60) | RARBPLK1THRATHRBALDH1A1 | |
| SCHEMBL23417713 | 0.82 | RARB (0.62) | RARBPLK1THRATHRBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110117158-A1 | INHIBITION AND DISPERSION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-TRIAZOLE DERIVATIVES | MELANDER CHRISTIAN | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117158-A1 | INHIBITION AND DISPERSION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-TRIAZOLE DERIVATIVES | TFPI, O60361, TFPI2 | RARB 2720/4885PLK1 1423/4885THRA 3472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.